Recent research has highlighted the potential of the Apelin/APJ system as a therapeutic target for neurological diseases, including Parkinson's disease. Studies have overturned previous findings on potential targets for Parkinson's disease, proposing a 'radically different' way of looking at the disease based on its biological basis, particularly α-synuclein. Neurologists and researchers are advocating for a shift in the classification of Parkinson's disease to focus on biological markers rather than clinical criteria.
A 'radically different' way of looking at #Parkinson's disease proposes by nuerologiste @KBI_UHN https://t.co/eIq1ScEris @medical_xpress https://t.co/7GSvdfMZVY
Rebooting the classification of Parkinson's disease on its biological basis, α-synuclein, instead of clinical criteria https://t.co/OotGPEi4sM https://t.co/31UOiWaN2S @TheLancetNeuro https://t.co/D581dKbwYo https://t.co/1RbaLKcAuf
A 'radically different' way of looking at #Parkinson'sDisease @TheLancet https://t.co/L74Er459kT
Research overturns previous findings on potential #Parkinson'sDisease target @WEHI_research @ScienceAdvances https://t.co/Z9zMZZq0pF https://t.co/lx7mcKaIDw
Apelin/APJ system: an emerging therapeutic target for neurological diseases https://t.co/L7oci6wmxd